Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|July 18, 2024

The Future of Manufacturing, Safety, and Collaboration

The panel highlights the need for continued research, collaboration between stakeholders, and a strategic approach to leveraging mRNA's capabilities to address unmet clinical needs.

The panel discussed the current state of mRNA medicine, highlighting gaps in research and development, and the need for continued innovation to improve safety and efficacy. The panelists also spoke on the importance of real-world clinical data and collaboration among stakeholders.

Discussion Topics

  • 00:07 - Current state and future potential of the mRNA field
  • 00:28 - Continued research needed to address gaps in mRNA technology, such as delivery mechanisms, immunogenicity, and long-term safety
  • 01:18 - Importance of real-world clinical data and building trust through collaboration between stakeholders
  • 03:37 - Need for a consortium of patient advocates, pharma, biotech, academia, and regulators to accelerate progress in mRNA medicine
  • 03:45 - Excitement about the potential of mRNA technology and the need to use it wisely to push boundaries

Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.